325 related articles for article (PubMed ID: 19432122)
21. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series.
Fedele S; Porter SR; D'Aiuto F; Aljohani S; Vescovi P; Manfredi M; Arduino PG; Broccoletti R; Musciotto A; Di Fede O; Lazarovici TS; Campisi G; Yarom N
Am J Med; 2010 Nov; 123(11):1060-4. PubMed ID: 20851366
[TBL] [Abstract][Full Text] [Related]
22. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
Marx RE; Sawatari Y; Fortin M; Broumand V
J Oral Maxillofac Surg; 2005 Nov; 63(11):1567-75. PubMed ID: 16243172
[TBL] [Abstract][Full Text] [Related]
23. Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment.
Dickinson M; Prince HM; Kirsa S; Zannettino A; Gibbs SD; Mileshkin L; O'Grady J; Seymour JF; Szer J; Horvath N; Joshua DE
Intern Med J; 2009 May; 39(5):304-16. PubMed ID: 19220531
[TBL] [Abstract][Full Text] [Related]
24. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.
Dimopoulos MA; Kastritis E; Bamia C; Melakopoulos I; Gika D; Roussou M; Migkou M; Eleftherakis-Papaiakovou E; Christoulas D; Terpos E; Bamias A
Ann Oncol; 2009 Jan; 20(1):117-20. PubMed ID: 18689864
[TBL] [Abstract][Full Text] [Related]
25. The use of bisphosphonates in cancer patients.
Wu S; Dahut WL; Gulley JL
Acta Oncol; 2007; 46(5):581-91. PubMed ID: 17562434
[TBL] [Abstract][Full Text] [Related]
26. Bisphosphonate-related osteonecrosis of the jaw: an overview.
Ruggiero SL
Ann N Y Acad Sci; 2011 Feb; 1218():38-46. PubMed ID: 20946580
[TBL] [Abstract][Full Text] [Related]
27. Safety profile of intravenous bisphosphonates.
Mehrotra B
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S24-7. PubMed ID: 18068487
[TBL] [Abstract][Full Text] [Related]
28. Bisphosphonates, hypercalcemia of malignancy, and osteonecrosis of the jaw.
Wynn RL
Gen Dent; 2005; 53(6):392-5. PubMed ID: 16366043
[No Abstract] [Full Text] [Related]
29. Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients.
Kyrgidis A; Triaridis S; Vahtsevanos K; Antoniades K
Expert Rev Anticancer Ther; 2009 Aug; 9(8):1125-34. PubMed ID: 19671032
[TBL] [Abstract][Full Text] [Related]
30. Bisphosphonate induced osteonecrosis of the jaw masquerading as tumor: a word of caution for oral surgeons and oncologists.
Chaturvedi P; Pai PS; Chaukar DA; Gupta S; D'cruz AK
Eur J Surg Oncol; 2010 Jun; 36(6):541-5. PubMed ID: 20071132
[TBL] [Abstract][Full Text] [Related]
31. Jaw osteonecrosis related to bisphosphonate treatment of bone metastasis.
Raffaelli L; Scaramuzzo L; Rossi Iommetti P; Graci C; Maccauro G; Manicone PF
J Biol Regul Homeost Agents; 2010; 24(2):115-21. PubMed ID: 20487624
[TBL] [Abstract][Full Text] [Related]
32. Bisphosphonates and osteonecrosis of the jaws: science and rationale.
Gutta R; Louis PJ
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Aug; 104(2):186-93. PubMed ID: 17448709
[TBL] [Abstract][Full Text] [Related]
33. A time for perspective on bisphosphonates.
Assael LA
J Oral Maxillofac Surg; 2006 Jun; 64(6):877-9. PubMed ID: 16713799
[No Abstract] [Full Text] [Related]
34. Bisphosphonates: a potential threat to your patients.
Dreiman BB
J Indiana Dent Assoc; 2005-2006 Winter; 84(4):4-9. PubMed ID: 16605211
[No Abstract] [Full Text] [Related]
35. Bisphosphonate complications including osteonecrosis of the jaw.
Mehrotra B; Ruggiero S
Hematology Am Soc Hematol Educ Program; 2006; ():356-60, 515. PubMed ID: 17124083
[TBL] [Abstract][Full Text] [Related]
36. Bisphosphonates and jaw osteonecrosis: the UAMS experience.
Clarke BM; Boyette J; Vural E; Suen JY; Anaissie EJ; Stack BC
Otolaryngol Head Neck Surg; 2007 Mar; 136(3):396-400. PubMed ID: 17321866
[TBL] [Abstract][Full Text] [Related]
37. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management.
Ruggiero SL; Fantasia J; Carlson E
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Oct; 102(4):433-41. PubMed ID: 16997108
[No Abstract] [Full Text] [Related]
38. Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
Crawford BS; McNulty RM; Kraut EH; Turowski RC
Cancer Invest; 2009 Dec; 27(10):984-8. PubMed ID: 19909013
[TBL] [Abstract][Full Text] [Related]
39. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
King AE; Umland EM
Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
[TBL] [Abstract][Full Text] [Related]
40. Bisphosphonates and osteonecrosis: potential treatment or serious complication?
Goytia RN; Salama A; Khanuja HS
Orthop Clin North Am; 2009 Apr; 40(2):223-34. PubMed ID: 19358907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
